Vanguard Group Inc Cel Sci Corp Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Cel Sci Corp stock. As of the latest transaction made, Vanguard Group Inc holds 2,411,246 shares of CVM stock, worth $988,610. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,411,246

Previous 2,411,246 -0.0%

Holding current value

$988,610

Previous $2.8 Million 8.65%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.11 - $1.85 $241,890 - $403,150	217,919 Added 9.94%	2,411,246 $2.8 Million
Q1 2024 May 10, 2024	BUY	$1.63 - $3.08 $185,335 - $350,205	113,703 Added 5.47%	2,193,327 $4.19 Million
Q4 2023 Feb 14, 2024	BUY	$1.07 - $3.07 $190,971 - $547,927	178,478 Added 9.39%	2,079,624 $5.66 Million
Q2 2023 Aug 14, 2023	SELL	$2.11 - $2.83 $16,888 - $22,651	-8,004 Reduced 0.42%	1,901,146 $4.58 Million
Q1 2023 May 15, 2023	BUY	$2.17 - $3.13 $23,336 - $33,660	10,754 Added 0.57%	1,909,150 $4.43 Million
Q4 2022 Feb 10, 2023	BUY	$1.99 - $3.52 $1,761 - $3,115	885 Added 0.05%	1,898,396 $4.46 Million
Q3 2022 Nov 14, 2022	BUY	$3.09 - $5.23 $109,682 - $185,644	35,496 Added 1.91%	1,897,511 $5.86 Million
Q2 2022 Aug 12, 2022	SELL	$2.58 - $4.99 $528,314 - $1.02 Million	-204,773 Reduced 9.91%	1,862,015 $8.38 Million
Q1 2022 May 13, 2022	SELL	$3.93 - $7.7 $43,599 - $85,423	-11,094 Reduced 0.53%	2,066,788 $8.12 Million
Q4 2021 Feb 14, 2022	SELL	$7.1 - $12.82 $385,948 - $696,882	-54,359 Reduced 2.55%	2,077,882 $14.8 Million
Q3 2021 Nov 12, 2021	BUY	$7.64 - $12.49 $497,776 - $813,773	65,154 Added 3.15%	2,132,241 $23.4 Million
Q2 2021 Aug 13, 2021	BUY	$8.68 - $27.49 $17.9 Million - $56.8 Million	2,067,087 New	2,067,087 $17.9 Million

Others Institutions Holding CVM

# of Institutions

Shares Held

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $17.8M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Cel Sci Corp Transaction History